Department of Ophthalmology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Zhejiang, People's Republic of China.
Am J Ophthalmol. 2012 Feb;153(2):291-299.e2. doi: 10.1016/j.ajo.2011.07.020. Epub 2011 Oct 13.
To compare long-term outcomes of full-bed deep lamellar keratoplasty (DLK) with penetrating keratoplasty (PK) for treating corneal leucoma caused by herpes simplex keratitis (HSK).
Retrospective, comparative, interventional case series.
setting: Institutional. patients: Inclusion criteria were patients with corneal scarring induced exclusively by HSK who underwent primary graft of full-bed DLK or PK and completed a minimum of 12 months postoperative follow-up. There was no significant difference of corneal scarring and vascularization between the 2 groups before surgery. Choosing PK or full-bed DLK depended on the patient's own willingness, except those patients with a preoperative endothelial cell count of less than 700 cells/mm(2) or whose endothelial cell count was undetectable were encouraged to undergo only PK. Exclusion criteria were patients with a past history of corneal perforation, nonprimary graft, non-HSK-related corneal scars, and failure to complete a minimum of 12 months of postoperative follow-up. Fifty-eight eyes of 58 patients in the full-bed DLK group and 63 eyes of 63 patients in the PK group met the inclusion criteria. main outcome measures: Postoperative managements, recurrence of HSK, graft rejection, graft survival rate, visual acuity, and corneal endothelial density.
The mean postoperative follow-up duration was 45.8 ± 30.9 months in the full-bed DLK group and 47.9 ± 27.2 months in the PK group (P = .70). As compared with the PK group, the full-bed DLK group experienced earlier suture removal (P = .01), needed fewer postoperative visits (P < .001), and had a higher proportion of eyes with full withdrawal of oral acyclovir (P < .001) and topical corticosteroid (P < .001). There were a total of 21 episodes of recurrent HSK in the PK group, more frequent than the 7 episodes in the full-bed DLK group, among which recurrent epithelial keratitis amounted to 13 episodes in the PK group, remarkably more frequent than the 1 episode in the full-bed DLK group. Twenty-six eyes (41.3%) encountered rejection episodes in the PK group, but no rejection episode was found in the full-bed DLK group (P < .001). In 14 eyes in the PK group, graft failure developed because of graft rejection, recurrence of HSK, or both, whereas only in 1 eye in the full-bed DLK group did graft failure develop because of recurrence of HSK (P = .001). The clear graft survival rate in the full-bed DLK group was significantly higher than that in the PK group (P = .01). Corneal endothelial cell density was stable from 1 month through 5 years in the full-bed DLK group, but 51.3% cell loss was found in the PK group at 5 years after surgery. At the last visit, 66.1% of eyes with full-bed DLK grafts and 50.9% of eyes with PK grafts achieved a best-correct visual acuity of 0.5 or better (P = .10).
Advantages of full-bed DLK over PK are no allograft rejection, longer graft survival, earlier drug withdrawal of topical steroid and oral acyclovir, less recurrence of HSK, and fewer follow-up visits. Full-bed DLK is preferable for treating HSK-induced corneal scarring with relatively healthy endothelium and with no history of perforation.
比较全层深板层角膜移植术(DLK)与穿透性角膜移植术(PK)治疗单纯疱疹性角膜炎(HSK)所致角膜白斑的长期疗效。
回顾性、对比性、干预性病例系列研究。
地点:机构。患者:纳入标准为仅由 HSK 引起角膜瘢痕,行初次全层 DLK 或 PK 移植,并完成至少 12 个月术后随访的患者。两组患者术前角膜瘢痕和血管化无显著差异。选择 PK 或全层 DLK 取决于患者自身意愿,但术前内皮细胞计数小于 700 个/mm²或内皮细胞计数无法检测的患者,仅鼓励行 PK。排除标准为有既往角膜穿孔史、非初次移植、非 HSK 相关角膜瘢痕、未完成至少 12 个月术后随访的患者。全层 DLK 组 58 只眼和 PK 组 63 只眼符合纳入标准。
术后处理、HSK 复发、移植排斥、移植物存活率、视力和角膜内皮密度。
全层 DLK 组的平均术后随访时间为 45.8 ± 30.9 个月,PK 组为 47.9 ± 27.2 个月(P =.70)。与 PK 组相比,全层 DLK 组更早去除缝线(P =.01),需要更少的术后就诊次数(P <.001),并且有更高比例的患者完全停用口服阿昔洛韦(P <.001)和局部皮质类固醇(P <.001)。PK 组共有 21 例 HSK 复发,比全层 DLK 组的 7 例更频繁,其中 PK 组复发性上皮性角膜炎有 13 例,明显多于全层 DLK 组的 1 例。PK 组有 26 只眼(41.3%)发生排斥反应,而全层 DLK 组未发生排斥反应(P <.001)。PK 组有 14 只眼因排斥反应、HSK 复发或两者同时导致移植物失功,而全层 DLK 组仅有 1 只眼因 HSK 复发导致移植物失功(P =.001)。全层 DLK 组的透明移植物存活率明显高于 PK 组(P =.01)。全层 DLK 组角膜内皮细胞密度在 1 个月至 5 年内保持稳定,但 PK 组在术后 5 年内发现 51.3%的细胞丢失。末次随访时,全层 DLK 组 66.1%的移植物和 PK 组 50.9%的移植物获得了最佳矫正视力 0.5 或以上(P =.10)。
全层 DLK 优于 PK 的优势在于无同种异体排斥反应、移植物存活率更长、更早停用局部皮质类固醇和口服阿昔洛韦、HSK 复发更少、随访次数更少。全层 DLK 适用于治疗单纯疱疹性角膜炎所致角膜瘢痕,且内皮相对健康、无穿孔史的患者。